Search
Spotlight on Australian Research: DL33, a Potential New Therapy for Niemann-Pick Type C
DL33, developed by Meizon Innovations, is preparing for the next stage of testing — and could one day change the future of childhood dementia. 💜
ANPDF
Oct 142 min read
Meizon Innovations Community Update | November 5, 2024
Meizon has been granted both Orphan Drug Designation & Rare Pediatric Disease designation by the US FDA.
ANPDF
Nov 6, 20241 min read